Pain therapy with high risk: One-sided presentation of the results from the latest phase III study on tanezumab in osteoarthritis pain

Pain

Volumn 155, Issue 11, 2014, Pages 2432-

  Panzram, Benjamin ^a   Schiltenwolf, Marcus ^a  

^a UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

OXYCODONE; PLACEBO; TANEZUMAB; MONOCLONAL ANTIBODY; NARCOTIC AGENT;

ANALGESIA; BONE NECROSIS; DISEASE COURSE; DRUG MEGADOSE; HIP OSTEOARTHRITIS; HUMAN; KNEE OSTEOARTHRITIS; LETTER; PATIENT SAFETY; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RISK ASSESSMENT; FEMALE; MALE; PAIN; ARTHRALGIA; JOINT PROSTHESIS; OSTEOARTHRITIS;

ANTIBODIES, MONOCLONAL, HUMANIZED; FEMALE; HUMANS; MALE; NARCOTICS; OXYCODONE; PAIN;

EID: 84923567322     PISSN: 03043959     EISSN: 18726623     Source Type: Journal    
DOI: 10.1016/j.pain.2014.08.006     Document Type: Letter

References (2)

1. Pfizer Inc. Tanezumab Arthritis Advisory Committee briefing document. Available at: ; 2012 [accessed 03.10.2012].
2. Spierings EL, Fidelholtz J, Wolfram G, Smith MD, Brown MT, West CR. A phase III placebo-and oxycodone-controlled study of tanezumab in adults with osteoarthritis pain of the hip or knee. PAIN- 2013;154:1603-12.